Review





Similar Products

3rd booster by pfizer (ba.4/5)  (Pfizer Inc)
90
Pfizer Inc 3rd booster by pfizer (ba.4/5)
Characteristics of Patients in Study Cohort
3rd Booster By Pfizer (Ba.4/5), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3rd booster by pfizer (ba.4/5)/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
3rd booster by pfizer (ba.4/5) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
3rd booster by pfizer (ba.4/.5)  (Pfizer Inc)
90
Pfizer Inc 3rd booster by pfizer (ba.4/.5)
Characteristics of Patients in Study Cohort
3rd Booster By Pfizer (Ba.4/.5), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3rd booster by pfizer (ba.4/.5)/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
3rd booster by pfizer (ba.4/.5) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Characteristics of Patients in Study Cohort

Journal: Open Forum Infectious Diseases

Article Title: Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study

doi: 10.1093/ofid/ofad475

Figure Lengend Snippet: Characteristics of Patients in Study Cohort

Article Snippet: 3rd Booster by Pfizer (BA.4/5) , 46 500 (56.7).

Techniques: Infection

Vaccine Effectiveness After the Second or Third Booster Doses by Bivalent Vaccine Among Adults Aged ≥65 Years During Omicron BA.5 Predominance

Journal: Open Forum Infectious Diseases

Article Title: Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study

doi: 10.1093/ofid/ofad475

Figure Lengend Snippet: Vaccine Effectiveness After the Second or Third Booster Doses by Bivalent Vaccine Among Adults Aged ≥65 Years During Omicron BA.5 Predominance

Article Snippet: 3rd Booster by Pfizer (BA.4/5) , 46 500 (56.7).

Techniques: Infection

Characteristics of Patients in Study Cohort

Journal: Open Forum Infectious Diseases

Article Title: Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study

doi: 10.1093/ofid/ofad475

Figure Lengend Snippet: Characteristics of Patients in Study Cohort

Article Snippet: 3rd Booster by Pfizer (BA.4/.5) , 11 (0.0).

Techniques: Infection

Vaccine Effectiveness After the Second or Third Booster Doses by Bivalent Vaccine Among Adults Aged ≥65 Years During Omicron BA.5 Predominance

Journal: Open Forum Infectious Diseases

Article Title: Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study

doi: 10.1093/ofid/ofad475

Figure Lengend Snippet: Vaccine Effectiveness After the Second or Third Booster Doses by Bivalent Vaccine Among Adults Aged ≥65 Years During Omicron BA.5 Predominance

Article Snippet: 3rd Booster by Pfizer (BA.4/.5) , 11 (0.0).

Techniques: Infection